Assistant Professor Anushree Chatterjee's research focuses on adopting integrated computational, systems and synthetic biology approaches to investigate fundamental, biotechnological and medically relevant issues including understanding the molecular mechanisms responsible for antibiotic and antiviral resistance, rational design of “next-generation smart antimicrobials,” and construction of synthetic genetic devices for a variety of biotechnological and bioenergy applications
Never one to sit still, Chemical and Biological Engineering Instructor Charlie Nuttelman has spent the past several summers writing a guidebook on hiking, mountain biking, snowshoeing, and cross country skiing. His book, titled Colorado Adventure Guide (Northern Edition), recently won a 2012 Writer's Digest Self-Publishing 1st Place Award and was featured in the De
BaroFold Inc., a pharmaceutical company focused on the patented Pressure Enabled Protein Manufacturing (PreEMT) technology invented in the labs of ChBE Professor Theodore Randolph and Dr. John Carpenter, has recently licensed its technology to both Boehringer Ingelheim and Nuron Biotech. Read more about these collaborative efforts below:
Ten active companies have been created since 1997 based on technologies invented wholly or in part by CU chemical and biological engineering students and their faculty supervisors. Chemical and biological engineering spinoff companies from CU-Boulder have raised nearly $410 million in follow-on funding, including grants, venture capital financing, U.S. Small Business Administration funding, and acquisitions, according to CU's Technology Transfer Office.
Recognizing the revenue potential of CU-licensed science moving to the commercial market, CU is looking at how to best maximize proceeds from technology transfer. The university plans to soon seek bids from consultants to help with this process. A 2012 article in Boulder’s Daily Camera discussed the potential of the JSCBB to result in new commercial compa
Christopher Bowman was one of ten to receive a 2012 Tech Commercialization Grant from the state of Colorado for developing inexpensive, highly-efficient synthetic nucleic acids for use in nano-assembly, bio-detection and other bio-functional applications.
OPX Biotechnologies was recognized as Bioscience Company of the Year in 2012 by the University of Colorado’s Technology Transfer Office. OPXBIO (Boulder, CO) is a venture-backed company making renewable bio-based chemicals and fuels that are lower cost, higher return and more sustainable than existing petr